🔎 Trials Near Me

Domov › Crohnova bolezen › Washington

Klinične študije za Crohnova bolezen v Washington

22 študij za Crohnova bolezen išče udeležence na lokacijah v Washington.

Mesta v Washington

Uradno besedilo študije (angleško)

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

  • Washington Gastroenterology - Tacoma ( Site 0295), Tacoma
Vključevanje udeležencevFaza 3
Vse starosti · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06651281

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • University of Washington ( Site 5115), Seattle
  • Washington Gastroenterology - Tacoma ( Site 5004), Tacoma
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Washington Gastroenterology - Bellevue /ID# 283966, Bellevue
  • Washington Gastroenterology - Tacoma /ID# 284143, Tacoma
  • The Vancouver Clinic /ID# 280497, Vancouver
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • GI Alliance, Bellevue
Vključevanje udeležencevFaza 4
Starost 18–80 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06581328

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Virginia Mason Hospital and Medical Center /ID# 265574, Seattle
  • Washington Gastroenterology - Tacoma /ID# 267302, Tacoma
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06548542

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • GI Alliance Tacoma, Tacoma
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07196722

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

  • University of Washington Medical Center, Seattle
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06233461

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Washington Gastroenterology - Tacoma, Tacoma
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • GI Alliance - Bellevue-Site Number: 8400143, Bellevue
  • The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184944

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  • Washington Gastroenterology- GIA, Tacoma
Vključevanje udeležencevFaza 4
Starost 18–70 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT06045754

Familial Inflammatory Bowel Disease Early Risk

  • Seattle Children's Hospital, Seattle
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 0–55 · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07791862

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • GI Alliance Tacoma, Tacoma
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07577843

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Seattle Children's Hospital, Seattle
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT05509777

A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

  • MultiCare Institute for Research & Innovation, Tacoma
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 3. avg. 2026 · NCT06100289

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • Multicare Health System Institute for Research and Innovation, Tacoma
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 22. jun. 2026 · NCT06405087

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Seattle Children's Hospital, Seattle
Vključevanje udeležencevFaza 4
Starost 6–17 · Vsi spoli · Posodobljeno 27. maj 2026 · NCT05781152

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  • Swedish Cancer Institute, Seattle
  • University of Washington Medical Center - Montlake, Seattle
Vključevanje udeležencevFaza 3
Starost 18–65 · Vsi spoli · Posodobljeno 27. maj 2026 · NCT06227910

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  • University of Washington, Seattle
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 27. apr. 2026 · NCT06456593

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

  • Seattle Children's Hospital, Seattle
Vključevanje udeležencevOpazovalna študija
Starost 6–21 · Vsi spoli · Posodobljeno 24. apr. 2026 · NCT06315179

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Bellevue
  • Mirador Therapeutics Selected Site, Silverdale
  • Mirador Therapeutics Selected Site, Tacoma
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 12. mar. 2026 · NCT07113522

Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

  • Seattle Children's Hospital, Seattle
Vključevanje udeležencev
Starost 8–21 · Vsi spoli · Posodobljeno 12. jun. 2025 · NCT06216899

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.